How do we achieve optimal cardiovascular risk reduction?

Clinical Cardiology

Volumn 24, Issue 8 SUPPL., 2001, Pages

  Gotto A M , Jr ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Coronary heart disease; Global risk assessment; Low density lipoprotein cholesterol; Statin therapy

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; GEMFIBROZIL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN; TIROFIBAN;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; EXPERIENCE; HIGH RISK PATIENT; HUMAN; MEDICAL DECISION MAKING; PATIENT CARE; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; SCORING SYSTEM;

EID: 19244387061     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960241503     Document Type: Review

References (15)

1. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
2. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
3. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
6. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
7. Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
8. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
9. Fibrates, dyslipoproteinaemia and cardio-vascular disease
10. Secondary prevention by raising HDL cholesterol and reducing triglycefides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) study
11. Clinical lipidology at the end of the millennium
12. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: A randomized controlled trial
13. Prediction of coronary heart disease using risk factor categories
14. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and Other Societies on Coronary Prevention
15. Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)